A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity

This phase II trial studies the how well donor stem cell transplant works in treating patients with high risk hematologic malignancies. Giving total-body irradiation and chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.

Study Overview

• Status: Completed
• Conditions: Hematopoietic and Lymphoid Cell Neoplasm
• Intervention / Treatment: Drug: Cyclophosphamide; Drug: Mycophenolate Mofetil; Drug: Tacrolimus; Radiation: Total-Body Irradiation; Procedure: Donor Lymphocyte Infusion; Procedure: Allogeneic Hematopoietic Stem Cell Transplantation

Detailed Description

Primary Objective:

1. To assess 2 year probability of OS in high risk patients undergoing a myeloablative 2 step HSCT utilizing strategies to decrease relapse.

Secondary Objective:

1. To assess relapse incidence at 2 years post-HSCT of patients undergoing treatment on this protocol.
2. To assess regimen related toxicity and GVHD incidence at 2 years post-HSCT and severity in patients undergoing treatment on this protocol.
3. To assess the consistency and pace of engraftment.
4. To assess the pace of T cell and B cell immune recovery.

• Study Type: Interventional
• Enrollment (Actual): 51
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Pennsylvania
    • Philadephia, Pennsylvania, United States, 19107
      • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

This treatment is for patients with high risk hematologic malignancies. High risk is defined as:

• Any patient with a hematologic malignancy in which allogeneic HSCT is pursued with the expectation of cure. Patients may have post-treatment residual disease, but the disease should be stable or minimally progressive and must be responsive to chemotherapy.
• Any patient with an untreated hematologic malignancy in which allogeneic HSCT is thought to be the sole or the best option for cure and in Patients without morphologic evidence of disease but with high risk features which would predict for relapsed despite remission at HSCT such as adverse cytogenetics, 3rd or greater CR, or failure to recover peripheral blood counts to normal ranges. While these patients do not have detectable disease by current methods, like all patients they have non-detectable disease which in their case is highly aggressive.
• Patients with uncommon diagnoses in which allogeneic HSCT is thought to be beneficial but are no comparable to the majority of patients on this protocol will not be counted in the statistical aims of the study and will be reported descriptively. The PI and at least one Co-I must document this exception in the study binder and the rationale for descriptive report. An example of a patient who may meet this criteria is someone with a malignancy that is an overlap of two different diagnoses or one whose malignancy is difficult to categorize. While this circumstance is expected to be rare, it will prevent patients with rare diagnoses to be treated off study and it will help maintain homogeneity of the study population.
• Patients must have one related donor who is HLA mismatched in the GVHD direction at two or more HLA loci (except as described below)
• Patients must have adequate organ function:
• Left Ventricular Ejection Fraction (LVEF) of ≥50%
• DLCO (adjusted for hemoglobin) ≥50% of predicted and FEV-1 ≥50%
• Adequate liver function as defined by a serum bilirubin ≤1.8, Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 x Upper Limit of Normal (ULN)
• Creatinine clearance of ≥ 60ml/min
• Karnofsky Performance Status (KPS) of ≥80% on the modified KPS tool (see Appendix)
• Patients must be willing to use contraception if they have childbearing potential
• Able to give informed consent
• Age ≥ 18 years of age

Exclusion Criteria:

• Modified KPS of <80%
• > 5 Comorbidity Points on the Hematopoietic Cell Transplant Co-Morbidity Index (HCT CI) (See Appendix) (Patients with greater than 5 points will be allowed for trial with approval of the PI and at least 1 Co-I not on the primary care team of the patient.) this is an adjustment to account for healthy patients who meet the spirit of this protocol but have histories that result in higher than HCT-CI 5 points. An example is a patient with a solid tumor malignancy in their remote history (adds 3 points to HCT-CI total) where the treatment for the malignancy occurred years to decades before and there has been complete recovery of toxicities.
• Human Immunodeficiency Virus (HIV) positive
• Active involvement of the central nervous system with malignancy
• Psychiatric disorder that would preclude patients from signing an informed consent
• Pregnancy, or unwillingness to use contraception if they have childbearing potential
• Patients with life expectancy of ≤ 6 months for reasons other than their underlying hematologic/oncologic disorder
• Alemtuzumab treatment within 8 weeks of HSCT admission
• ATG within 8 weeks of HSCT administration
• Inability to tolerate cyclophosphamide or undergo total body irradiation at the doses specified in the treatment plan.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Treatment (TBI, DLI, chemotherapy, HSCT); Patients undergo Total-Body Irradiation (TBI) twice daily on days -10 to -8 and and donor lymphocyte infusion (DLI) on day -6. Patients receive cyclophosphamide IV on days -3 and -2, tacrolimus IV beginning on day -1 and then orally at least 2 or 3 days prior to discharge with taper starting on day 42, and mycophenolate mofetil IV twice daily on days -1 to 28. Patients undergo Allogeneic Hematopoietic Stem Cell Transplantation on day 0.

Drug: Cyclophosphamide; Given IV; Other Names: CTX; (-)-Cyclophosphamide; Carloxan; Ciclofosfamida; Ciclofosfamide; Clafen; CP monohydrate; Cycloblastin; Cyclophospham; Cyclophosphamid monohydrate; WR- 138719; 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate; 1-bis(2-chloroethyl)-amino-1-oxo-2-aza-5-oxaphosphoridin monohydrate; 6055-19-2; Drug: Mycophenolate Mofetil; Given IV; Other Names: Cellcept; 115007-34-6; 128794-94-5; 724229; Drug: Tacrolimus; Given IV; Other Names: Prograf; Hecoria; Fujimycin; Protopic; 109581-93-3; 717865; Radiation: Total-Body Irradiation; Undergo Total Body Irradiation; Other Names: Total Body Irradiation; Procedure: Donor Lymphocyte Infusion; Undergo Donor Lymphocyte Infusion; Other Names: DLI; Donor Leukocyte Infusion; Procedure: Allogeneic Hematopoietic Stem Cell Transplantation; Undergo Hematopoietic Stem Cell Transplantation; Other Names: HSC; HSCT

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival (OS)	Will be tested using an exact one-sided binomial test with alpha 0.05. The trial will be considered successful if the null hypothesis of 45% 2-year OS is rejected. In addition, the exact binomial 95% confidence interval for 2-year OS will be computed.	At two years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of graft failure	Should be less than 10%	Up to 2 years
Incidence of non-relapse mortality	Should be less than 20% at 100 days	Up to 2 years

Collaborators and Investigators

• Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
• Investigators: Principal Investigator: Usama Gergis, MD, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Publications and helpful links

Helpful Links

• Thomas Jefferson University Hospital
• Sidney Kimmel Cancer Center

Study record dates

Study Major Dates

• Study Start (Actual): January 31, 2017
• Primary Completion (Actual): December 2, 2025
• Study Completion (Actual): December 2, 2025

Study Registration Dates

• First Submitted: January 24, 2017
• First Submitted That Met QC Criteria: January 24, 2017
• First Posted (Estimated): January 26, 2017

Study Record Updates

• Last Update Posted (Actual): January 29, 2026
• Last Update Submitted That Met QC Criteria: January 27, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Hematologic Neoplasms; Organic Chemicals; Investigative Techniques; Therapeutics; Fatty Acids; Lipids; Hydrocarbons; Acids, Acyclic; Carboxylic Acids; Macrolides; Lactones; Phosphoramide Mustards; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Phosphoramides; Organophosphorus Compounds; Radiotherapy; Caproates; Cyclophosphamide; Mycophenolic Acid; Tacrolimus; Whole-Body Irradiation
• Other Study ID Numbers: 16D.606; JT 9551 (Other Identifier: JeffTrial Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes